TSTickerStar
Company alerts/HCWB
HCWB company alerts

HCWB updates worth following

TickerStar monitors official filings, investor releases, earnings, and call updates for HCWB. Subscribe to HCWB alerts to receive concise, source-linked alerts when TickerStar detects a meaningful company update.

Official-source feed

Recent HCWB alert previews

TickerStar filters routine noise and surfaces investor-relevant filings, releases, earnings, and call updates.

EarningsOfficial company source

HCW Biologics Reports Q3 2026 Financial Results

HCW Biologics reported Q3 2026 revenues of $55,463, up from $15,606 in Q3 2025, and net loss of $3.2 million compared to $4.6 million in the prior year period. For the nine months ended September 30, 2026, revenues were $6.7 million versus $27,222 in the prior year period, primarily driven by the Trimmune licensing agreement, while net loss improved to $5.0 million from $8.7 million. The company disclosed substantial doubt about its ability to continue as a going concern for at least 12 months without additional...

Read source-backed brief
SEC filingSEC filing

HCWB 10-Q filed 2026-11-16 | Key takeaways

HCWB filed its 10-Q; the most relevant disclosure change is expanded Revenue recognition - Trimmune license: The Company recognized $6.3 million of revenue allocated to the Licensed IP at the point in time control transferred to Trimmune upon closing on March 16, 2026, and $403K of Services revenue for the nine months ended September 30, 2026; a contract liability of. Customer concentration: Trimmune (Beijing Trimmune Biotech Co. Ltd.) represented 99% of revenue.

Read source-backed brief
Debt offeringSEC filing

HCW Biologics Secures $10 Million Debt Financing from Streeterville Capital

HCW Biologics Inc. entered into a Notes Purchase Agreement with Streeterville Capital, LLC on November 3, 2026, issuing two secured promissory notes totaling $10.2 million in original principal for gross proceeds of $10.0 million. The transaction includes a Promissory Note A-1 of $3.2 million (with $240,000 OID and $30,000 transaction costs) bearing 8% interest and a Promissory Note B of $7.0 million bearing 5% interest, both maturing in 24 months. Net cash of $3.0 million was received at closing on November 4,...

Read source-backed brief